

ATC codes: J01DD01

Indication	Inflammatory and other diseases of prostate	ICD11 code: GA91.Z
INN	Cefotaxime	
Medicine type	Chemical agent	
Antibiotic groups	 WATCH	
List type	Core	
Additional notes	3rd generation cephalosporin of choice for use in hospitalized neonates.	
Formulations	Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt)	
EML status history	First added in 2017 (TRS 1006) Changed in 2023 (TRS 1049)	
Sex	Male	
Age	Adolescents and adults	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more about patents .	
Wikipedia	Cefotaxime 	
DrugBank	Cefotaxime 	

Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

EML recommendations: Inflammatory and other diseases of prostate

First choice

Second choice

MILD TO MODERATE

ciprofloxacin

ceftriaxone

cefotaxime

SEVERE

ceftriaxone

co-prescribed with [amikacin](#)

cefotaxime

co-prescribed with [amikacin](#)

